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+By May 1972, 60 patients had under-
gone orthotopic or auxiliary hepatic trans-
plantation at the University of Colorado 
Medical Center and the Veterans Adminis-
tration Hospital, Denver. A number of these 
patients benefited from the operation 
liver Transplantation 
Sixty patients with severe liver disease have 
undergone hepatic transplantation in Denver. 
Deterrents to success have been mechanical 
vascular and biliary complications, graft 
rejections, severe infections, and recurrence 
of hepatic malignancy. Nonetheless, 
I J, 4 and 2 of the patients have survived 
beyond one, two and three years, 
respectively. Avenues for further 
improvement are discussed. 
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through, at least, temporary return to a 
normal life. This report presents the indica-
tions, the problems of management, and 
the results. 
The Patients 
In all instances the indication for the 
transplantation was life-threatening liver 
disease for which no other form of treat-
ment was available. Initially, nonresectable 
malignant liver tumors were believed to be 
an important indication for total liver re-
placement. However, the high incidence of 
tumor recurrence has prompted a mora-
torium in transplantation of the liver in 
these cases. 
Among the nonneoplastic diseases, bili-
ary atresia has been the most common 
single indication for liver transplantation. 
More recently the number of patients with 
cirrhosis and chronic aggressive hepatitis 
undergoing the operation has increased. 
When the first attempts were made to re-
place the liver in patients with benign liver 
disease, the recipients were in end-stage 
hepatic failure and gastrointestinal bleed-
ing, hepatic coma, or renal insufficiency 
usually was present. Obviously their poor 
condition reduced the chances of success. 
POSTGRADUATE MEDICINE 
Recent'ly an attempt has been made to 
operate before the advent of this proces-
sion of terminal complications. 
Because of the high proportion of pa-
tients with biliary atresia, about 45 percent 
of the recipients have been younger than 
five years of age. No other organ trans-
plantation has been carried out in such a 
high proportion of small children. 
All the hepatic homografts have been 
obtained from cadaveric donors. In more 
than a dozen of the first cases, in situ cool-
ing and removal of the liver were begun 
after cardiac arrest had occurred. Since 
the acceptance of the brain death criteria 
in 1968, the grafts have been obtained 
without such an ischemic insult. At the 
same time it has become possible to delay 
the removal of the graft until completion 
of the recipient hepatectomy, a condition 
that obviates the need for ex vivo graft 
preservation measures. 
Until 1969 an attempt often was made 
to select donor-recipient combinations on 
the basis of HL-A histocompatibHity. Since 
then the results of such matching have been 
found not to correlate with clinical results 
in recipients of nonrelated rena'i and other 
kinds of homografts'·2 and this kind of 
effort has been deemphasized. Present re-
quirements fo!' a donor include only a com-
patible ABO blood group and absence of 
malignancy or generalized sepsis. Reason-
able similarity in size of donor and re-
cipient is desirable. 
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The Transplantation 
Orthotopic transplantation (total replace-
ment of the liver with anatomic reconstruc-
tion of the vasculature) was carried out in 
56 of the 60 patients (figure 1). The neces-
sary cross-clamping of vena cava and por-
tal vein is to'lerated for at least 90 minutes. 
In the remaining four patients (all of whom 
had nonneoplastic liver disease), the pa-
tient's own liver was left in place and the 
graft was inserted in a heterotopic position 
(figure 2). However, the possible advan-
tages of retaining the residual function of 
the diseased liver are offset by several fac-
tors. Portal hypertension remains unrelieved 
unless a shunt procedure is performed. The 
diseased :Iiver may continue to be a threat 
to life as the site of hepatoma; this was 
observed as an incidental finding in speci-
mens from two patients in our series. The 
abdominal overcrowding has led to a very 
high incidence of pulmonary complications. 
Finally, residual function in a host liver may 
enable it, by a process loosely termed in-
terliver competition, to lessen the chances 
of good function and survival of the trans-
plant. 3 
While portal or caval vascular compli-
cations have not been common, in five pa-
tients fatal hepatic arterial thrombosis de-
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Figure 1. Orthotopic hepatic transplantation. b, c. Arterial reconstructions used in two patients 
when homograft had a double arterial blood supply: 
two anastomoses (b) and anastomosis of donor a. Anatomic reconstruction of inferior vena cava 
above and below the liver and of the portal vein 
and the hepatic artery . Biliary drainage is with 
cholecystoduodenostomy after lig,ation of the graft 
as well as the patient's common duct. 
aorta to recipient aorta (c). Several other variations 
have been necessary in other patients. 
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Figure 2. Heterotopic hepatic transplantation. 
a. The incisions. 
I.V.c. 
P.V. 
b. Portacaval shunt performed before transplantation . 
c. The hepatic graft revascularized in the lower abdomen. Portal inflow is from the patient's 
inferior vena cava; the inferior end of the graft vena cava 'h as been closed. Biliary drainage is 
with cholecystoenterostomy to a Roux-Y loop . 
In other patients, the portal vein has been anastomosed to the splenic or mesenteric vein 
to provide inflow of splanchnic blood into the graft. 
Reproduced from Ha/grimson CG, et a/: Arch Surg 93: 1 07, 1966. Copyright 1966, American Medical Association. 
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veloped immediately after operation or 
within a few weeks. This complication was 
seemingly related to the small size of the 
vessels, especially in children, and to ar-
terial anomalies with hepatic branches 
emerging from the superior mesenteric or 
other anomalous sources. The multiple ef-
fects of the liver on blood coagulation 
might have been a contributing factor. 
In the majority of the patients the re-
construction of the biliary tract has been 
with anastomosis of the graft gallbladder 
to the recipient duodenum (figure 1). Al-
though obstruction caused by technical or 
infectious complications involving the cystic 
duct has occurred in six of these patients,3,4 
this method of reconstruction remains the 
preferred procedure, as it does not un-
necessarily sacrifice potentially useful tis-
sue. The method carries a very low inci-
dence of bile leakage, and in the event 
of malfunction, a secondary procedure can 
be performed either by implanting the 
common bile duct in the duodenum or by 
end-to-end anastomosis of the graft and 
host common ducts. 
Early Postoperative Management 
The implantation of a liver damaged by 
ischemia is followed by hypogl'ycemia, se-
vere clotting abnormalities, and develop-
ment of a third fluid space with severe 
electrolyte and acid-base disturbances.3 
'However, the early course after implantation 
of a minimally injured liver usuaUy is not 
much different from what is seen following 
other kinds of major abdominal: surgery. 
Careful monitoring of arterial blood gases 
and of serum potassium and glucose, with 
swift and appropriate adjustmel1ts in ther-
apy, is important. Most patients in our ex-
perience have benefited from intravenous 
administration of albumin and diuretics 
over the first several postoperative days. 
Vitamin K is given daily to support the syn-
thesis of clotting factors. A triple combina-
tion of antibiotics effective against a broad 
spectrum of Gram-negative and Gram-posi-
tive bacteria is given during the first post-
operative weeks. 
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Graft Rejection and Immunosuppression 
Some animals, particu,larly the pig and 
the baboon, receiving hepatic homografts 
have survived for long periods without im-
munosuppression, and it has been con-
cluded that the liver enjoys a privileged 
immunologic status in these species. Such 
a situation also may exist in man, but if 
so, any advantage is minor. Occurrence of 
rejection episodes in human recipients of 
hepatic homografts is the rule rather than 
the exception; 
So far, no absolutely specific tests for 
diagnosis of hepatic homograft rejection 
have become available. The most charac-
teristic changes in the standard liver func-
tion tests include an increase in serum bili-
rubin and in alkaline phosphatase parallel-
ing concomitant intrahepatic cholestasis. 
If rejection progresses, rises in serum trans-
aminases, prolongation of prothrombin 
time, and other indications of cellul'ar in-
jury eventuate (figure 3). 
The biochemical tests poorly differentiate 
graft rejection from other pathologic 
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Figure 3. Course of a two year old child with biliary atresia. The first hepatic graft was 
rejected in two months. Note the hyperbilirubinemia and the marked elevation of alkaline 
phosphatase accompanying a moderate increase in serum transaminases. 
After the second hepatic transplantation, graft function was excellent at first. Later there was 
evidence of acute rejection, but this time the process could be reversed. The patient lived another 
12 months. Immunosuppression was with azathioprine, prednisone, and horse and rabbit 
antihuman lymphocyte globulin. 
processes such as biliary obstruction, infec-
tious hepatitis, and hepatic injury caused 
by drugs. 'Intravenous cholangiograms, 
technetium and rose bengal radioisotope 
scans, needle biopsy, and serum testing for 
Australia antigen all can aid in the dif-
ferential diagnosis. 
The extensive experience with renal 
transplantation provides the foundation for 
the immunosuppressive regimens used in 
human hepatic transplantation . The first 
recipients undergoing transplantation from 
1963 to 1966 were given azathioprine and 
prednisone.5 Since 1966, horse antihuman 
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lymphocyte globulin also has been given 
during the fint several postopelrative 
months3 (figure 3). Recently cyclophospha-
mi.de has been found to be as effective 
an immunosuppressant in man as azathio-
prine6 and, since it may 'be I'ess hepato-
toxic, has been used in place of azathio-
prine during the first several postoperative 
months in the 15 most recent cases in our 
series (figure 4) . For chronic treatment, 
azathioprine may still 'be preferable, owing 
to its less toxic effect on bone marrow. 
During the first weeks, prednisone is 
given ,in very high doses. Subsequently the 
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Figure 4. Course of a 14 year old boy with Wilson's disease. Fundion af the orthotopic 
hepatic homograft as measured with standard biochemical tests was excellent, except for an 
early period when bilirubin and alkaline phosphatase rose. At the same time, Australia 
antigen was present in serum, suggesting serum hepatitis. 
Note rapid normalization of serum ceruloplasmin and copper after transplantation . 
Cyclophosphamide was used as an immunosuppressant initially. After nine months, 
azathioprine was given instead. 
dosage is reduced gradually. If evidence of 
graft rejection appears, dosage is again 
increased (figure 3). With time and "graft 
acceptance," prednisone requirements di-
minish. The mechanism of this latter phe-
nomenon is poorly understood, but it is a 
prerequisite of long-term success, as the 
side effects of prolonged high-dose pred-
nisone use are prohibitive. 
Early or late failure to control homo-
graft rejection has been a major cause of 
death in about one-third of our hepatic 
homograft recipients. In a few patients a 
second transplantation was carried out 
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when graft insufficiency due to rejection 
became severe. One patient survived for 
12 months after the second operation. 
The Compromised Host 
The dilemma of chronic immunosuppres-
sion is to provide enough therapy to pre-
vent rejection, but not so much that the 
patient dies of immunologic invalidism. In 
a given case this fine balance may not be 
achievable. With a frequency equa'l to that 
of failure to give enough treatment to pre-
vent rejection, overtreatment has been re-
sponsible for infectious complications. 
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Figure 5. Noca r-
dial infection in a 
29 year old pa-
tient who died 21 
months after he-
patic transplanta-
tion was perform-
ed for chronic ag-
gressive hepatitis. 
a. Fungal abscess 
in the homograft. 
b. Nocardia as-
teroides in the 
brain . (Brown and 
Sten stain, x 200.) • 
a 
,b 
An exa mple of these complications was 
a rece nt infection with a fungus, N ocardia, 
man ifested by inflammatory skin nodules 
in a rec ipient whose graft had functioned 
we ll for 21 months. In spite of three months' 
trea tment with su lfona mides, the patient 
died with d isse mina ted fungal abscesses 
involving a lmost eve ry organ (figure 5). 
The infecting orga nism was one of the op-
portun ists tha t become pathogenic in im-
munolog ically compromised hosts. Others 
a re Candida, Aspergillus and Cryptococcus 
a mong the fungi ; cytomegalovirus, herpes 
simplex, a nd var icella-zoster among the 
vi ruses; a nd the noncla ssified Pneumocystis 
carinii. Infections with all these organisms 
have occurred in our series, and in about 
a third of the patients the infection has 
contributed to death. 
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In addition, the liver recipients have hod 
a high incidence of septicemia with Gram-
negative bacteria of the types existing in 
the endogenous bowel flora. Evidence in-
dicates that during biliary obstruction or 
a rejection episode, the hepatic graft read-
ily becomes infected with intestinal bac-
teria, which then enter the systemic circu-
lation (figure 6). In some patients, large 
septic infarcts have developed, probably 
as a consequence of uncontrolled rejec-
tion. 3 Frequent blood cultures are manda-
tory in caring for these recipients, and 
growth of Gram-negative bacteria in the 
bloodstream is strong evidence of graft ob-
struction, rejection, or serious injury from 
other causes, including hepatic vascular 
throm bosis. 
In all of five patients surviving beyond 
two months following total liver replace-
ment for hepatic carcinoma, carcinomatosis 
developed. In several the tumor recurrence 
included the hepatic homograft (figure 7). 
Another highl,y malignant hepatic tumor, 
the hemangioendothelioma, infiltrates the 
liver to on extent that leads to rapid liver 
failure , but metastasis has been thought to 
be uncommon. RecenHy a patient with this 
disease underwent liver replacement and 
was found to have widespread metastases 
within three months. 
It is possible that the rapidity and extent 
of occurrence of metastases in these pa-
tients are a consequence of loss of the 
"immunologic surveillance" by which mutant 
cells can be eliminated or restricted in their 
growth potential/ Be that as it may, the 
very high incidence of tumor recurrence 
has dampened, if not eHminated, enthu-
siasm for liver replacement as treatment 
of malignant hepatic disease. 
Late Results 
Survival beyond one, two and three 
years has been achieved in 11,4 and 2 
of the patients, respectively (table 1). Nine 
patients are presently olive, of whom four 
underwent transplantation more than one 
year ago, two more than two years ago, 
and one more than three years ago. 
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Figure 6. An explanation of the predisposition 
of liver homograft recipients to bacterial sepsis. 
Presumably the invading microorganisms enter 
via the portal vein or the reconstructed 
biliary tract. 
Figures I and 6 adapted from Starzl TE: 
Ann Surg 168:392, 1968. 
The largest group of long-term survivors 
is found among the children treated for 
biliary atresia. Of 20 patients treated more 
than 12 months ago, six lived for at least 
one year. Promising results have been re-
corded also in the treatment of Wilson's 
disease. 8 Two teen-age boys with this dis-
ease underwent transplantation 37 and 117 
months ago, respectively. One of them was 
in hepatic failure, and the other had severe 
neurologic involvement associated with cir-
rhosis of the liver. Biopsy specimens have 
shown no accumulation of copper in the 
grafts, and in the second patient, markedly 
suppressed serum levels of copper and 
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Figure 7. Metastases in a 15 year old patient 
who died five months after hepatic 
transplantation for hepatoma. 
c. Hepatic homograft has been virtually 
replaced by tumor. 
b. Extensive pulmonary metastases. 
Figure 3 adapted from and figure 7 reproduced 
from Starzl TE, Putnam CW. 3 
ceruloplasmin have normalized (figure 4). 
The findings are consistent with, but do 
not prove, the hypothesis that the metabolic 
defect in Wilson's disease is liver-based. 
Both patients are alive and well. 
Among the patients with benign liver dis-
ease, the worst results of transplantation 
have been in those with Laennec's or biliary 
cirrhosis, none of whom have survived be-
yond one year. These results probably re-
flect the unfavorable case selection men-
tioned earlier and should not discourage 
further efforts to operate on such patients. 
The only patient with a malignancy in 
our series in whom metastases did not de-
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velop was a child treated two and two-
thirds years ago for biliary atresia. In this 
case a small hepatoma was an incidental 
finding . Caine, of Cambridge, and Daloze, 
of Montreal, have each cured one case of 
primary hepatic malignancy. 
Neither in our small series nor among 
recipients treated ot other centers has there 
been an instance of extended survival of 
a patient undergoing heterotopic hepatic 
transplantation for liver failure. 
The most important reasons for the 
failures include mechanical complications 
such as hepatic arterial thrombosis and 
biliary obstruction or fistula, uncontrollable 
graft rejection, severe infections, and re-
currence of hepatic malignancy. 
The Future 
Although several patients have lived for 
more than two years after hepatic trans-
plantation, the incidence of long-term sur-
vival remains low. Several avenues for im-
provement are obvious. (1) Operation 
should be done at an optimum stage, be-
fore the patient's condition is agonal. (2) 
Extensive collaboration within the medical 
community regarding utilization of organs 
from patients with brain death would in-
crease the chances of treating more pa-
tients at the right time. (3) Careful pre-
operative evaluation of vascular and bili-
ary anatomy might prevent some of the 
technical complications. (4) Further im-
provements in the means for controlling 
the immune response are crucial. 
Even now, a major upgrading of results 
should be attainable. Because of discour-
agement with our program in 1971, a 
moratorium was declared and was in effect 
TABLE 1. ORTHOTOPIC HEPATIC 
TRANSPLANTATION 
Survivors 
Indications Total 
1+ 2+ 3+ 
Years Years Years 
Biliary 26* 6t 3 1 
atresia 
Cirrhosis 10 
Wilson's 2 2 1 1 
disease 
Chronic 5 1 
aggressive 
hepatitis 
Carcinoma 12 2 
Sarcoma 1 
- - -
-
56 11 4 2 
Now alive 9 4 2 1 
*One patient, who is alive at 32 months, had 
a small hepatoma. tOne patient received two 
homografts. 
for the last four months of the year. In 
1972 the program was resumed and extra 
attention was given to many small details. 
The surviva'i in new cases has been five of 
six. The one death was caused by hepatic 
arterial thrombosis in an infant three months 
of age whose first homograft, from an 
anencephalic newborn, was too small and 
whose second homograft implanted three 
months later, from a donor five years ' of 
age, was too large. 
With improved results the ,indict:ltions 
for hepatic transplantation could be ex-
panded. In addition to the numerous pa-
tients suffering from severe destructive he-
patic disease, a large number of patients 
with liver-based errors of metabolism could 
benefit from the procedure. 
Address reprint requests to Dr. Starzl. 
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